Literature DB >> 11606858

Expression and clinical significance of antinuclear antibody in hepatitis C virus infection.

Y C Peng1, S C Hsieh, D Y Yang, C F Tung, W H Hu, W N Huang, G H Chen.   

Abstract

BACKGROUND: The prevalence of antinuclear antibody (ANA) has been documented in patients with hepatitis C virus (HCV) infection. We attempted to determine the titer and to characterize the patterns and clinical significance of ANA in HCV infection. STUDY: Forty-eight consecutive patients with positive anti-HCV antibody and positive HCV RNA were included in this study. Sera from patients were tested for ANA and anti-smooth muscle antibody by indirect immunofluorescence. Serum aminotransferase, alkaline phosphatase, alpha-fetoprotein, and cryoglobulin levels also were determined.
RESULTS: Eleven (23%) of 48 HCV-infected patients were positive for ANA. Antinuclear antibody revealed speckled pattern in 10 (91%) of the 11 ANA-positive HCV-infected patients. Twenty (54%) of 37 ANA-negative HCV-infected patients had detectable pattern with equivocal titer (titer <1.5). The ANA pattern was speckled in all 20 patients. Hepatitis C virus-infected patients with positive ANA were older than the HCV-infected patients with negative ANA (62.90 +/- 11.05 years vs. 56.46 +/- 14.94 years, respectively; p < 0.1). Serum levels of aspartate aminotransferase (39.36 +/- 14.98 IU/L vs. 30.70 +/- 23.15 IU/L, p < 0.05), alkaline phosphatase (189.00 +/- 75.63 IU/L vs. 122.41 +/- 40.88 IU/L, p < 0.01), and alpha-fetoprotein (47.72 +/- 80.47 pg/dL vs. 7.00 +/- 8.28 pg/dL, p < 0.01) were higher in ANA-positive HCV-infected patients than in ANA-negative HCV-infected patients, respectively. There were no significant differences in gender, alanine aminotransferase, anti-smooth muscle antibody, or cryoglobulin between the two groups.
CONCLUSIONS: Antinuclear antibody was present in 11 (23%) of 48 patients with HCV infection in our study. Speckled pattern is the major expression pattern of ANA in HCV infection. Antinuclear antibody-positive HCV-infected patients have significantly higher serum aspartate aminotransferase, alkaline phosphatase, and alpha-fetoprotein levels than ANA-negative HCV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606858     DOI: 10.1097/00004836-200111000-00012

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  9 in total

1.  Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers.

Authors:  Ediz Dalkılıç; Mustafa Ferhat Öksüz; Ayşe Nur Tufan; Aysun Özbek; Ali Nizamoğlu; Mürside Esra Dolarslan; Belkıs Nihan Coşkun; Yavuz Pehlivan
Journal:  Eur J Rheumatol       Date:  2015-03-31

2.  Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody.

Authors:  Takashi Himoto; Seiji Nakai; Fumihiko Kinekawa; Hirohito Yoneyama; Akihiro Deguchi; Kazutaka Kurokochi; Tsutomu Masaki; Shoichi Senda; Reiji Haba; Seishiro Watanabe; Mikio Nishioka; Shigeki Kuriyama
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

Review 3.  Autoantibodies in chronic hepatitis C: A clinical perspective.

Authors:  Janaína Luz Narciso-Schiavon; Leonardo de Lucca Schiavon
Journal:  World J Hepatol       Date:  2015-05-18

4.  Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment.

Authors:  Ana Beatriz da Silva Sacerdote; Norma Arteiro Filgueira; Silvana de Barros Barreto; Andréa Dória Batista; Edmundo Pessoa Lopes
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

5.  Clinical significance of the detection of antinuclear antibodies in patients with acute hepatitis a.

Authors:  Yeon Seok Seo; Kwang Gyun Lee; Eun Suk Jung; Hyonggin An; Ji Hoon Kim; Jong Eun Yeon; Kwan Soo Byun; Hyung Joon Yim; Hong Sik Lee; Soon Ho Um; Chang Duck Kim; Ho Sang Ryu
Journal:  Gut Liver       Date:  2011-08-18       Impact factor: 4.519

6.  The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C.

Authors:  Hermann E Wasmuth; Christian Stolte; Andreas Geier; Christoph G Dietrich; Carsten Gartung; Johann Lorenzen; Siegfried Matern; Frank Lammert
Journal:  BMC Infect Dis       Date:  2004-02-13       Impact factor: 3.090

Review 7.  Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis.

Authors:  Takashi Himoto; Mikio Nishioka
Journal:  Auto Immun Highlights       Date:  2013-02-22

8.  Imported West Nile virus infection in Europe.

Authors:  P E Charles; H Zeller; B Bonnotte; A L Decasimacker; J B Bour; P Chavanet; B Lorcerie
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883

9.  Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations.

Authors:  Andrew J Gilman; An K Le; Changqing Zhao; Joseph Hoang; Lee A Yasukawa; Susan C Weber; John M Vierling; Mindie H Nguyen
Journal:  BMJ Open Gastroenterol       Date:  2018-05-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.